[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P - CAS 96736-12-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C79H109N19O12
Molecular Weight:
1516.85
COA:
Inquire
Targets:
Neuropeptide Y receptor
Description:
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is a broad spectrum neuropeptide inverse agonist and antagonist. It acts as a full inverse agonist for the ghrelin receptor (EC50 = 5.2 nM) and antagonist at tachykinin, bradykinin, CCK and bombesin receptors. It induces apoptosis and inhibits cancer cell growth in vitro.
Brife Description:
neuropeptide inverse agonist
Sequence:
D-Arg-Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-Leu
Synonyms:
Antagonist D
MSDS:
Inquire
InChIKey:
XVOCEQLNJQGCQG-ACRSGXKRSA-N
InChI:
InChI=1S/C79H109N19O12/c1-46(2)38-59(68(83)100)91-70(102)60(39-47(3)4)92-73(105)64(43-51-45-88-56-28-14-12-25-53(51)56)95-72(104)61(40-48-20-7-5-8-21-48)93-74(106)63(42-50-44-87-55-27-13-11-24-52(50)55)94-69(101)57(32-33-67(82)99)89-71(103)62(41-49-22-9-6-10-23-49)96-76(108)66-31-19-37-98(66)78(110)58(29-15-16-34-80)90-75(107)65-30-18-36-97(65)77(109)54(81)26-17-35-86-79(84)85/h5-14,20-25,27-28,44-47,54,57-66,87-88H,15-19,26,29-43,80-81H2,1-4H3,(H2,82,99)(H2,83,100)(H,89,103)(H,90,107)(H,91,102)(H,92,105)(H,93,106)(H,94,101)(H,95,104)(H,96,108)(H4,84,85,86)/t54-,57+,58+,59+,60+,61+,62-,63-,64-,65+,66+/m1/s1
Canonical SMILES:
CC(C)CC(C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC4=CNC5=CC=CC=C54)NC(=O)C(CCC(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)C8CCCN8C(=O)C(CCCN=C(N)N)N
1.High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist.
Holst B;Cygankiewicz A;Jensen TH;Ankersen M;Schwartz TW Mol Endocrinol. 2003 Nov;17(11):2201-10. Epub 2003 Aug 7.
Ghrelin is a GH-releasing peptide that also has an important role as an orexigenic hormone-stimulating food intake. By measuring inositol phosphate turnover or by using a reporter assay for transcriptional activity controlled by cAMP-responsive elements, the ghrelin receptor showed strong, ligand-independent signaling in transfected COS-7 or human embryonic kidney 293 cells. Ghrelin and a number of the known nonpeptide GH secretagogues acted as agonists stimulating inositol phosphate turnover further. In contrast, the low potency ghrelin antagonist, [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance P was surprisingly found to be a high potency (EC50 = 5.2 nm) full inverse agonist as it decreased the constitutive signaling of the ghrelin receptor down to that observed in untransfected cells. The homologous motilin receptor functioned as a negative control as it did not display any sign of constitutive activity; however, upon agonist stimulation the motilin receptor signaled as strongly as the unstimulated ghrelin receptor. It is concluded that the ghrelin receptor is highly constitutively active and that this activity could be of physiological importance in its role as a regulator of both GH secretion and appetite control.
2.[D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors.
Jarpe MB;Knall C;Mitchell FM;Buhl AM;Duzic E;Johnson GL J Biol Chem. 1998 Jan 30;273(5):3097-104.
Substance P derivatives are potential therapeutic compounds for the treatment of small cell lung cancer and can cause apoptosis in small cell lung cancer cells in culture. These peptides act as broad spectrum neuropeptide antagonists, blocking calcium mobilization induced by gastrin-releasing peptide, bradykinin, cholecystokinin, and other neuropeptides. We show that [D-Arg1,D-Phe5,D-Trp7,9, Leu11]substance P has unique agonist activities in addition to this described antagonist function. At doses that block calcium mobilization by neuropeptides, this peptide causes activation of c-Jun N-terminal kinase and cytoskeletal changes in Swiss 3T3 fibroblasts and stimulates migration and calcium flux in human neutrophils. Activation of c-Jun N-terminal kinase is dependent on the expression of the gastrin-releasing peptide receptor in rat 1A fibroblasts, demonstrating that the responses to the peptide are receptor-mediated. We hypothesize that [D-Arg1,D-Phe5,D-Trp7,9, Leu11]substance P acts as a biased agonist on neuropeptide and related receptors, activating certain guanine nucleotide-binding proteins through the receptor, but not others.
3.Receptor-activated currents in mouse fibroblasts expressing transfected bombesin receptor subtype cDNAs.
Kusano K;Gainer H;Battey JF;Fathi Z;Wada E Am J Physiol. 1993 Oct;265(4 Pt 1):C869-76.
BALB/c 3T3 cells do not normally express receptors for bombesin-like peptides [bombesin (Bn), gastrin-releasing peptide (GRP), and neuromedin B (NmB)]. Transfection of BALB/c 3T3 cells with complementary DNA-encoding GRP receptors or NmB receptors leads to stable expression of functional GRP receptors (GRP Rt) or NmB receptors (NmB Rt), respectively, which are coupled to cell membrane ion channels. Whole cell current analysis using patch electrodes shows that the activation of these newly expressed receptors induces cation conductance increases, most frequently a Ca(2+)-activated plasma membrane K+ conductance. The dose-response (peak-current) relations of both transfected receptor subtypes were sigmoidal and exhibited threshold activation concentration in the picomole range and the saturation of responses to higher concentrations than 10(-8) M. The GRP Rt responded about equally to GRP, NmB, and Bn when compared at equimolar levels, despite their known difference in binding affinity for the three peptides (GRP, Bn > NmB). In contrast, for the NmB Rt, the NmB was more potent than GRP or Bn. Among four GRP/Bn-receptor antagonists tested, the [D-Phe6]Bn(6-13) ethyl ester suppressed GRP Rt responses at low concentrations (10(-7) M).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Neuropeptide Y receptor Products


CAS 186185-03-5 BMS-193885

BMS-193885
(CAS: 186185-03-5)

BMS-193885 is a potent and selective neuropeptide Y1 receptor antagonist with IC50= 5.9nM, Ki = 3.3 nM. BMS-193885 displays > 47, > 100, > 160, > 160 and > 160-...

CAS 263849-50-9 S 25585

S 25585
(CAS: 263849-50-9)

S 25585 is a potent neuropeptide Y (NPY) Y5 receptor antagonist (IC50 = 5.4, > 1000, > 10 000 and > 10 000 nM at Y5, Y1, Y2 and Y4 receptors, respectively) with...

CAS 123583-37-9 Peptide YY (3-36) human

Peptide YY (3-36) human
(CAS: 123583-37-9)

Peptide YY (3-36) human, a short (36-amino acid) peptide released by cells in the ileum and colon in response to feeding, is a NPY Y2 receptor agonist. PYY (3-3...

CAS 143896-17-7 M40

M40
(CAS: 143896-17-7)

M40 is a potent, non-selective antagonist of galanin receptor, and has no effect on chow or fat intake.

CAS 90880-35-6 Neuropeptide Y (human, rat)

Neuropeptide Y (human, rat)
(CAS: 90880-35-6)

Neuropeptide Y (human, rat) is a widely distributed endogenous neuropeptide involved in the control of food intake, sexual behavior and blood pressure. NPY has ...

CAS 125580-28-1 [Leu31,Pro34]-Neuropeptide Y (porcine)

[Leu31,Pro34]-Neuropeptide Y (porcine)
(CAS: 125580-28-1)

[Leu31,Pro34]-Neuropeptide Y (porcine) is a high affinity neuropeptide Y Y1 receptor agonist (Ki = 0.54 nM).

BIIE 0246
(CAS: 246146-55-4)

BIIE 0246 is a potent, selective and non-peptide antagonist which binds to the neuropeptide Y Y2 receptor (IC50 = 15 nM) with > 650-fold selectivity over Y1, Y4...

CAS 342577-38-2 Velneperit

Velneperit
(CAS: 342577-38-2)

Velneperit is a once-daily, oral, centrally acting, small molecule neuropeptide Y (NPY) Y5 receptor antagonist.

Chemical Structure

CAS 96736-12-8 [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P

Quick Inquiry

Verification code

Featured Items